Ruud Smits

Learn More
It is the year 2005 and the Managing Director of Biomat has a problem. Her spin-off firm builds replacement human organs using metagenic technology, but after two years of success Biomat is at a crossroads. Should it stick to metagenics, which is costly and prone to production problems, or should it use the latest ultragenic approaches-still unproven but(More)
  • 1